7a72c46a-6e10-4e68-a822-4d8d67eeee32
GENETIC VARIANTS IN ITALIAN EARLY-ONSET AD
Early-onset Alzheimer's disease (EOAD) is the most common form of early-onset dementia. Although three major genes have been identified as causative, the genetic contribution to the disease remains unsolved in many patients. Recent studies have identified pathogenic variants in genes representing a risk factor for developing AD and in causative genes for other degenerative dementias as responsible for EOAD. To study them further, we investigated a panel of candidate genes in 102 Italian EOAD patients, 45.10% of whom had a positive family history and 21.74% with a strong family history of dementia. We found that 8.82% of patients carried pathogenic or likely pathogenic variants, including a novel variant, in PSEN1, PSEN2, or APP, and 7.84% showed homozygosity for the ?4 APOE allele. Additionally, 9.80% of patients had a moderate risk allele in PSEN1, PSEN2, or TREM2 genes. Besides, we observed that 19.60% of our patients carried a variant in genes associated with other neurodegenerative diseases. The combination of these variants contributes to explaining 48% of cases with a definite familiarity and 34% of sporadic forms. Our results confirm the importance of extensive genetic screening in EOAD for clinical purposes, to select patients for future treatments and to contribute to the definition of overlapping pathogenic mechanisms between AD and other forms of dementia.
Early-onset Alzheimer's disease (EOAD) is the most common form of early-onset dementia. Although three major genes have been identified as causative, the genetic contribution to the disease remains unsolved in many patients. Recent studies have identified pathogenic variants in genes representing a risk factor for developing AD and in causative genes for other degenerative dementias as responsible for EOAD. To study them further, we investigated a panel of candidate genes in 102 Italian EOAD patients, 45.10% of whom had a positive family history and 21.74% with a strong family history of dementia. We found that 8.82% of patients carried pathogenic or likely pathogenic variants, including a novel variant, in PSEN1, PSEN2, or APP, and 7.84% showed homozygosity for the ?4 APOE allele. Additionally, 9.80% of patients had a moderate risk allele in PSEN1, PSEN2, or TREM2 genes. Besides, we observed that 19.60% of our patients carried a variant in genes associated with other neurodegenerative diseases. The combination of these variants contributes to explaining 48% of cases with a definite familiarity and 34% of sporadic forms. Our results confirm the importance of extensive genetic screening in EOAD for clinical purposes, to select patients for future treatments and to contribute to the definition of overlapping pathogenic mechanisms between AD and other forms of dementia.